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Abstract
Background: Essential hypertension is a significant risk factor for cardiovascular diseases. Emerging research
suggests a role of DNA methylation in blood pressure physiology. We aimed to investigate epigenetic associations
of promoter related CpG sites to essential hypertension in a genome-wide methylation approach.
Methods: The genome-wide methylation pattern in whole blood was measured in 11 obese patients before and
six months after Roux-en-Y gastric bypass surgery using the Illumina 450 k beadchip. CpG sites located within
1500 bp of the transcriptional start site of adjacent genes were included in our study, resulting in 124 199 probes
investigated in the subsequent analysis. Percent changes in methylation states and SBP measured before and six
months after surgery were calculated. These parameters were correlated to each other using the Spearman’s rank
correlation method (Edgeworth series approximation). To further investigate the detected relationship between
candidate CpG sites and systolic blood pressure levels, binary logistic regression analyses were performed in a
larger and independent cohort of 539 individuals aged 19–101 years to elucidate a relationship between EH and
the methylation state in candidate CpG sites.
Results: We identified 24 promoter associated CpG sites that correlated with change in SBP after RYGB surgery
(p < 10−16). Two of these CpG loci (cg00875989, cg09134341) were significantly hypomethylated in dependency
of EH (p < 10−03). These results were independent of age, BMI, ethnicity and sex.
Conclusions: The identification of these novel CpG sites may contribute to a further understanding of the
epigenetic regulatory mechanisms underlying the development of essential hypertension.
Keywords: Essential hypertension, Epigenome-wide association study, Whole methylome analysis, Bariatric
surgery, EHMT2, FUSSEL18, SKOR2, Corl2
Background
Hypertension (HT) is the leading risk factor for mortal-
ity worldwide and is ranked third as a cause of
disability-adjusted life-years. Today, nearly one billion
people suffer from HT, making it an important public-
health issue [1]. The high prevalence of HT and its iden-
tification as a major risk factor for secondarily occurring
diseases of the cardiovascular system and the kidneys
underlines the necessity to study the pathophysiological
mechanisms and molecular biological susceptibility
factors underlying the development of this disease.
The heritability of HT is estimated to range between
40 and 60 % [2]. Besides the well-established link
between genetic and non-genetic factors (such as e.g.
obesity, alcohol or salt intake) in the pathogenesis of HT,
there is increasing evidence that epigenetic mechanisms
might be able to contribute to the development of HT
[3]. Especially the missing heritability conundrum of HT
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combined with its late onset and progressive nature
point to epigenetics as a potential modulator of blood
pressure (BP). Epigenetic patterns are potentially revers-
ible and are influenced by nutritional-environmental
factors as well as gene-environment interactions. These
factors have been shown to play an important role in the
development of complex multifactorial diseases, such as
those affecting the cardiovascular system [3]. An in-
creasing number of studies suggest a significant role of
epigenetic modifications in the progression of EH [4–6].
An elementary pillar in antihypertensive therapy is the
reduction of weight. It has been shown that a modest
weight loss by 10 % already lowers the BP significantly
[7, 8]. Surgical interventions such as Roux-en-Y gastric
bypass (RYGB) surgery are the most efficient therapeutic
options for a significant reduction of weight and an im-
provement of associated cardiovascular and metabolic
co-morbidities today [9]. The reduction in BP typically
seen after surgery has been suggested to be an effect of
both caloric restriction and weight loss [10, 11].
Age significantly impacts the pathogenesis of EH [12]
and different sets of genes control BP regulation at dif-
ferent ages [13]. Furthermore, men have a significantly
higher risk to develop cardiovascular disease than age-
matched premenopausal women [14]. In addition to
disease risk alterations due to age, body weight and
gender, the prevalence of EH varies in dependency of
ethnic origin. So show individuals of Hispanic origin
significantly lower BP levels than white individuals [15].
Inflammatory processes have also been shown to play a
significant role in the pathophysiology of EH, whereby
the relative contribution of inflammation to BP variabil-
ity remains to be fully clarified [16].
To date, very few studies have investigated the associ-
ation between DNA methylation and BP levels in a
genome-wide study approach. In this study, we perform
a whole methylome analysis in obese patients under-
going RYGB surgery to examine whether and to what
extent changes in DNA methylation patterns are
associated with changes in systolic blood pressure
(SBP). Newly identified candidate CpG loci are further
investigated and confirmed as risk loci for EH in a
targeted analysis performed in a large cohort of 539
individuals.
Methods
Characterization of the discovery group and validation
cohort
Study population of the discovery dataset
Samples used in this study have been collected in the
frame of a study that has been previously published [17].
The study population included twelve obese patients, who
underwent bariatric surgery at the Klinik Stephanshorn in
St. Gallen, in 2009–2011. All subjects were eligible for
bariatric surgery by international guidelines [18] and gave
their written informed consent to participating in the
study. In 2008 and prior to enrollment, the canton St.
Gallen ethics committee approved the study.
Subjects were fasting at the time of blood sampling for
whole methylome determination and measurements.
Blood was drawn according to standard procedures and
BP was measured one time after an overnight fast, in a
sitting position, after 5 min of relaxation, before and six
months after surgery. One patient suffered from a
known genetic disorder and was not eligible for further
analysis, resulting in a sample size of 11 individuals.
The surgical procedure was performed by connecting a
20–30 ml large gastric pouch from the upper stomach to
the proximal jejunum, thereby considerably limiting the
gastric residence time of nutrients. Furthermore, an anasto-
mosis of the biliopancreatic limb to the jejunum was estab-
lished 150 cm distal from the pouch-jejunal connection.
Study population of the validation dataset
Data for the validation study cohort were obtained from
publicly available sources (ArrayExpress databases, ac-
cession number E-GEOD-40279). This cohort was com-
posed of two different ethnic groups, comprising 426
Caucasians and 230 individuals of Mexican origin, aged
19 to 101 years old [19]. BMI was measured for all
subjects. Information on blood pressure status (EH or
normotensive) was provided to us by Zhang et al., and
was available for 540 individuals. Information on intake
of any anti-hypertensive medications, DBP or SBP, was
not available. One patient was described as having
‘borderline’ EH, and was therefore excluded in our
analysis, resulting in a sample size of 539 observations.
Methylation profiling
Extraction of genomic DNA was performed by the
phenol-chloroform method [20], after which it was bisul-
fite converted using the EZ DNA Methylation – GoldTM
kit (ZymoResearch, USA). The bisulfite converted DNA
was hybridized to the Illumina 450 k methylation chip
(Illumina, San Diego, CA, USA) to measure DNA methy-
lation in 485 577 individual CpG sites. In the discovery
group, DNA obtained from blood samples taken from the
same individual before and six months after surgery were
hybridized to the same physical chip. The array was im-
aged using the Illumina iScan system (Illumina, San Diego,
CA, USA), determining the percentile methylation for
each CpG site across the study groups.
CpG site annotation
We used the expanded annotation table provided by Price
et al. [21] to define the associated gene, distance to the
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closest TSS and the surrounding CpG density for each
investigated CpG site. Probes are located in either a high-
density islands (HC), intermediate-density islands (IC) or
in non-islands. The local CpG density has been shown to
influence the role of methylated cytosines, whereby
methylation influences the transcriptional efficacy stron-
ger in high-density islands as compared to non-islands
[22]. To ensure that variation in methylation reflect
expression levels, the analysis was limited to CpG-sites
located within 1500 base pairs up and upstream of the
transcriptional start site. Wagner et al. revealed that the
relationship between DNA methylation and gene expres-
sion is closely related within this region [23].
Data processing
To quantify methylation levels of CpG sites, raw data
were transformed into β-values using the GenomeStudio
software (Illumina, San Diego, CA, USA). Further data
processing was performed using the R package Illumina
Methylation Analyzer (IMA). CpG sites were excluded if
located on sex determining chromosomes, covering
known SNP loci or if 75 % of subjects exhibited a detec-
tion p-value greater than 5×10-05.
Adjustment of type I and type II probes and removal of
batch effects
CpG sites of the Illumina chip belong to type I or type II
probes, which significantly differ in distribution and dy-
namic range of DNA methylation. As this design may
bias downstream analyses, methylation data was further
adjusted by peak correction and quantile normalization
to adjust for probe type differences. The ComBat func-
tion [24] was used to adjust for batch effects.
After all steps of data processing procedures were
performed, 124 199 probes remained to be included in
the subsequent analysis.
Statistical analysis
All statistical analyses were perfomed using R statistics,
version 3.0.2.
‘Hmisc’ package of R statistic was used for discovery
group analysis. When sample sizes exceed nine observa-
tions, as was the case in our study, this package by default
uses algorithm AS 89 and an Edgeworth series approxima-
tion to calculate correlation coefficients and p-values for
Spearman’s rank correlation coefficients. We applied this
method of analysis to our data. Percentage change in
methylation states and SBP were calculated, measured
before and six months after RYGB surgery. These pa-
rameters were correlated in using the Spearman’s rank
correlation method, resulting in 124 199 individual cor-
relation analyses. P-values were adjusted for multiple
testing using Bonferroni correction method [25]. Ad-
justed p-values < 0.05 were considered significant. To
exclude potential confounding effects of age, BMI and
levels of fasting plasma glucose, the same method of
analysis was performed, correlating percentile changes
in methylation states to these variables. Paired t-tests
were performed to evaluate changes in continuous vari-
ables independently from each other, e.g. the methylation
state of a CpG site before and six months after surgery.
In a second step, we aimed to further investigate the
association of changed methylation patterns in candidate
CpG sites with EH in a second cohort (verification co-
hort). For this purpose, binary logistic regressions of EH
to the methylation states were performed, accounting
for age, BMI, ethnicity and sex as co-variables.
Results
Behavior of clinical outcome variables in the discovery
group and verification cohort
In the discovery group, comprising patients who underwent
bariatric surgery, we initially aimed to identify candidate
CpG sites, in which modifications of the epigenetic profile
are associated with changes in SBP levels after surgical
intervention. As expected, patients reduced their BMI by
24 % six months after surgery. Furthermore, diastolic blood
pressure (DBP) and SBP levels were significantly lower after
the operation (Table 1).
CpG sites that correlated with SBP in the discovery
group were further investigated for an association with
EH in the verification cohort. This cohort comprised
539 subjects of Caucasian or Hispanic descent, aged 19
to 101 years and subgrouped into EH or normotensive
individuals. While no significant differences with regard
to ethnicity were observed in the hypertensive group,
Hispanics were overrepresented in the normotensive
study arm. In the hypertensive study arm white subjects
were older than subjects of Hispanic origin. Further-
more, the individuals showed a significantly higher age
and BMI in the hypertensive group as compared to the
individuals in the normotensive study arm (Table 1).
Methylation changes at distinct CpG sites correlate with
the change in SBP in obese patients before and six
months after RYGB surgery
We performed a genome-wide methylation analysis in
obese patients before and 6 months after RYGB surgery
and compared the global methylation change with
changes in SBP before and after the intervention. In case
of 24 CpG sites changes in methylation significantly cor-
related with the percentile change in SBP six months
after RYGB surgery (Table 2). The changed methylation
states of these CpG sites did not correlate with age, BMI
or DBP, underlining the specificity of the observed asso-
ciations. Methylation changes of four of these probes
correlated also significantly with fasting plasma glucose
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levels (Table 3). Overall, no significant differences in
the methylation of the 24 detected CpG sites were
detected before and six months after surgical inter-
vention (Table 2).
The methylation of two CpG sites that correlated with
SBP levels in the RYGB cohort are differentially
methylated in the confirmative cohort showing EH
Two candidate CpG sites (cg00875989; cg09134341) that
we found to be associated with SBP in the RYGB cohort,
were significantly hypomethylated in EH (Table 2).
These sites are located in the promoter regions of the
genes Euchromatic histone-lysine n-methyltransferase 2
(EHMT2) and ski family transcriptional corepressor 2
(SKOR2), respectively. The results were confirmed in
the verification cohort by comparing methylation levels
in normotensives and EH by binary logistic regression
analysis and were independent of age, BMI, ethnicity
and sex (Table 2).
Discussion
By genome-wide investigating the DNA methylation
profile in whole blood of RYGB patients we identified
two novel CpG sites that were associated with SBP levels
and EH. Our findings show that increased methylation
of these probes correlate strongly with significant reduc-
tion in SBP levels observed after RYGB surgery. In
agreement with this, EH is associated with significantly
lower methylation levels of the identified CpG sites
compared to normotensive subjects. These results were
derived from two independent study populations encom-
passing healthy, obese, young, middle-aged and elderly
Table 1 Characteristics of subjects included into the study
Discovery groupa Verification cohort
Parameter EH NT
N 11 275 264
Men: Women (n (%)) 7:4 140 (50.9):135 (49.1) 127 (48.1):137 (51.9)
Caucasian: Hispanic (n (%)) 11:0 132 (48.0):143 (52.0) 97 (36.7):167 (53.3)
Age (years, n (%))
0–19 – – 1 (0.4)
20–29 1 (9.1) – 10 (3.8)
30–39 1 (9.1) 7 (2.5) 11 (4.2)
40–49 4 (36.4) 26 (9.5) 38 (14.4)
50–59 3 (27.3) 70 (25.5) 48 (18.2)
60–69 2 (18.2) 73 (26.5) 66 (25.0)
70–79 – 59 (21.5) 51 (19.3)
80–89 – 34 (12.4) 33 (12.5)
90–99 – 5 (1.8) 6 (2.3)
100+ – 1 (0.4) –
Mean (SD) 46.9 (11.9) 64.9 (13.2) 62.3 (16.4)
Body mass index (BMI)
BaselineA 47.9 (6.9) 29.6 (6.1) 26.9 (4.8)
Post surgeryB 36.0 (6.7) – –
p: A vs. B 6.21E–09 – –
Diastolic blood pressure
BaselineA 91.6 (12.8) N/A N/A
Post surgeryB 82.7 (7.2) – –
p: A vs. B 1.48E–02 – –
Systolic blood pressure
BaselineA 144.5 (16.0) N/A N/A
Post surgeryB 125.9 (14.7) – –
p: A vs. B 6.78E–03 – –
Abbreviations: EH essential hypertension, NT normotensive, RYGB Roux-en-Y gastric bypass, N/A not applicable
aThis group comprises patients who underwent RYGB surgery. Values at baseline and post-surgery are shown as mean values (SD). P-values were calculated by
means of pairwise t-tests, contrasting values at baseline and six months after RYGB-surgery (p: A vs. B). A one-tailed p-value <0.05 was considered significant
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subjects, respectively. The observations suggest that the
identified epigenetic risk sites are associated with hyper-
tension and cardiovascular disease across different ages
and weight groups.
To our knowledge, this is the first study investigating
epigenome-wide associations of whole blood methylation
patterns and SBP levels in a longitudinal manner in a
RYGB cohort. By observing RYGB patients before and
after intervention, we were able to take the dynamic
quality of BP and associated methylation changes into
account. Thus, our study allows more specifically eluci-
dating BP associated methylation changes as compared
to e.g. a case-control study set up, where the likelihood
of confounding due to interindividual variance and e.g.
(long-time) HT induced secondary methylation changes
is much higher. By choosing a genome-wide study ap-
proach using the Illumina 450 k methylation chip, it was
possible to comprehensively investigate 124 199 CpG
sites with regard to changes in methylation patterns in a
hypothesis-free and thereby unbiased manner. The two
CpG sites did not change significantly in their methyla-
tion state after RYGB surgery, providing further grist to
the mill that their association to SBP is not limited ex-
clusively to this intervention but rather attributable to
the general population.
Euchromatic histone-lysine n-methyltransferase 2
(EHMT2; also termed G9a) is a protein lysine histone
methyltransferase (PKMT), encoded by EHMT2 and
expressed in high levels in peripheral blood leukocytes
[26]. G9a is responsible for the majority of dimethylation
Table 2 CpG sites significantly correlated with SBP and EH
Discovery groupa (n=11) Verification cohortb (n=539)
% DNA Methylation (SD) Spearman’s rank correlation
coefficients (SBP)
Binary logistic regressions
(EH)
Gene Illumina ID Distance to
TSS
BaselineA After surgeryB p A vs. B Coef. p p (Bonf.) % DNA Methylation
(SD)
Exp (B) p p (Bonf.)
MCCC1 cg00161968 27 5.36 (1.1) 5.9 (1.7) ns 0.93 <10E–16 <10E–16 7.5 (4.3) – ns ns
SKOR2 cg00875989 1500 33.2 (1.7) 33.6 (3.6) ns (0.92) <10E–16 <10E–16 37.5 (4.2) 0.92 1.16E–03 2.79E–02
VGLL3 cg06251539 375 9.3 (2.4) 8.7 (1.88) ns 0.92 <10E–16 <10E–16 14.5 (3.1) – ns ns
WSB1 cg08706258 125 4.3 (1.1) 4.2 (0.7) ns 0.93 <10E–16 <10E–16 4.8 (0.8) – ns ns
EHMT2 cg09134341 (1332) 91.0 (2.8) 91.8 (1.2) ns (0.92) <10E–16 <10E–16 89.3 (1.9) 0.84 9.58E–04 2.30E–02
TCF12 cg10146710 1132 2.4 (0.5) 2.4 (0.4) ns 0.92 <10E–16 <10E–16 2.3 (1.0) – ns ns
MAP2K4 cg10596925 (242) 12.1 (3.4) 13.0 (2.0) ns 0.95 <10E–16 <10E–16 10.7 (2.9) 0.94 4.98E–02 ns
FAM54A cg10640093 (196) 3.8 (1.0) 4.1 (0.7) ns 0.94 <10E–16 <10E–16 3.0 (0.7) – ns ns
SORBS1 cg12360759 598 7.4 (1.7) 7.4 (1.0) ns 0.92 <10E–16 <10E–16 9.1 (1.3 0.82 6.33E–03 ns
DDX55 cg15612682 232 6.0 (1.5) 6.1 (0.8) ns 0.93 <10E–16 <10E–16 5.6 (1.0) – ns ns
ATXN1L cg16076930 380 19.0 (2.8) 20.5 (5.1) ns 0.94 <10E–16 <10E–16 21.1 (2.8) – ns ns
EFEMP1 cg16118212 227 12.7 (4.4) 10.7 (2.9) ns 0.92 <10E–16 <10E–16 17.3 (6.2) – ns ns
CRKL cg16500810 (197) 1.5 (0.3) 1.6 (0.9) ns 0.92 <10E–16 <10E–16 0.6 (0.6) – ns ns
STEAP3 cg18643762 (211) 2.9 (1.0) 3.4 (1.0) ns (0.93) <10E–16 <10E–16 1.7 (1.3) – ns ns
CPEB4 cg20841073 648 10.7 (2.2) 10.3 (2.7) ns 0.93 <10E–16 <10E–16 5.2 (2.0) 0.85 2.37E–03 ns
RHOBTB2 cg21344124 302 3.2 (0.7) 2.8 (1.1) ns 0.92 <10E–16 <10E–16 2.2 (0.7) 1.34 1.96E–02 ns
ATXN1 cg21996137 (185) 2.0 (0.7) 1.8 (0.6) ns 0.92 <10E–16 <10E–16 1.6 (0.7) 1.42 1.60E–02 ns
TSSK1B cg22011370 525 89.9 (2.6) 89.9 (2.9) ns (0.95) <10E–16 <10E–16 90.6 (3.3) – ns ns
SPPL2A cg22295383 (104) 5.2 (1.3) 4.9 (1.1) ns 0.94 <10E–16 <10E–16 4.2 (1.3) – ns ns
BHLHA9 cg23945265 1003 45.4 (4.2) 46.9 (3.2) ns (0.92) <10E–16 <10E–16 45.7 (5.2) 0.96 2.58E–02 ns
CHCHD5 cg25521086 (58) 4.0 (0.8) 3.8 (0.7) ns 0.95 <10E–16 <10E–16 3.1 (1.2) – ns ns
NRTN cg25544164 342 99.0 (0.3) 9.1 (0.2) ns 0.94 <10E–16 <10E–16 99.1 (0.5) – ns ns
Abbreviations: EH essential hypertension, Exp(B) log odds ratio, ns not significant, RYGB Roux-en-Y gastric bypass, SBP systolic blood pressure, SD standard
deviation, TSS transcription start site
aThis group comprises patients who underwent RYGB surgery. bResults were derived from binary logistic regressions of EH (yes/no) to % CpG site methylation,
age, BMI, ethnicity and sex. Log odds ratios and p-values refer to the CpG site in focus. P-values for DNA methylation levels were calculated by paired t-tests,
contrasting methylation levels at baseline and six months after RYGB-surgery (p: A vs. B). GWAS results for SBP were calculated by genome-wide analyses of
Spearman's rank correlation coefficients using algorithm AS 89 and an Edgeworth series approximation. Unless specified as SD, parenthesis “()” implies
negative numbers
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of histone H3 at lysine 9 (H3K9me2), a major repressive
histone methylation mark in euchromatin [27]. Cells lack-
ing G9a display a drastic reduction in this modification
[27]. Lehnertz et al. identified a critical role for G9a in T
helper cell differentiation in vitro and in vivo. Notably,
expression of interleukin 17 (IL-17) was dysregulated in T
helper cells in the absence of G9a or in the presence of a
specific G9a methyltransferase inhibitor, which is associ-
ated with a loss of H3K9me2 at the IL-17 locus. G9a is
thus a critical component in the inhibition of IL-17
expression [28]. Several recent studies confirmed the
concept that cytokines produced by T cells and other
inflammatory cells contribute to hypertension [29–35].
Harrison et al. identified IL-17 as a novel pro-
inflammatory cytokine that contributes to the develop-
ment of hypertension. Notably, Harrison et al. found that
mice lacking IL-17 do not sustain hypertension after treat-
ment with the hypertensive stimulus angiotensin II [36].
Furthermore, in contrast to the effects seen in wild-type
mice, IL-17−/− mice do not exhibit an increase in super-
oxide production and there is no reduction in endothelial-
dependent vasodilatation after treatment with angiotensin
II [36]. IL-17 further promotes chemotaxis of other proin-
flammatory cells by stimulating release of chemokines [37,
38]. In agreement with this, Harrison et al. also noted a re-
duction in vascular accumulation of leukocytes in IL-17
−/− mice treated with angiotensin II [36]. Thus, IL-17
may influence the vascular pathophysiology of hyperten-
sion by its direct effects - increasing superoxide produc-
tion and reducing endothelial-dependent vasodilatation -
and by guiding other pro-inflammatory cells to the peri-
vascular tissue. Further studies are needed to confirm the
role of IL-17 in human EH, and to investigate whether the
observed methylation changes in G9a reflect gene expres-
sion levels, H3K9me2 activity and IL-17 expression levels.
The global role of G9a leaves of course space for add-
itional regulatory functions in HT by, for example, incorp-
orating also effects on the induction of Th2 lineage-
specific cytokines interleukin 4, interleukin 5 and interleu-
kin 14 [27] and the cellular response to stress by inhibition
of interleukin 6 and interleukin 8 transcription [39].
Nevertheless, in light of these recent scientific advances in
the study of hypertension, we suggest that G9a putatively
contributes to the pathophysiology of EH by influencing
IL-17 expression (Fig. 1).
SKI family transcriptional co-repressor 2 (SKOR2),
also termed functional SMAD-suppressing 235 element
on chromosome 18 (FUSSEL18) [40] or Corl2 [41], was
first described by Arndt et al. and 236 identified as a
novel homolog to the SKI family of transcriptional co-
repressors [40]. While little is known about its role in
human leukocytes, cancer studies have identified this
protein as a potential tumor suppressor in head and
neck squamous cell carcinomas [42]. Further research is
needed before any speculation as to the functional rele-
vance of SKOR2 in EH can be made.
Our study is limited by the fact that BP was measured
only once in a sitting position in the discovery cohort,
which putatively causes a higher variance of the outcome
variable than expected with repeated and averaged mea-
surements. We took the most important confounders
available, such as age, gender, BMI and ethnicity, into con-
sideration, on the association analysis between methyla-
tion and EH. However, potential confounding factors e.g.
dietary patterns, comorbidities or intake of any antihyper-
tensive medication may be able to induce changes in
methylation patterns as well. Furthermore, our study per-
tained to promoter associated CpG sites in DNA methyla-
tion in whole blood largely consisting of leukocytes, which
are composed of different cell populations with unique
Table 3 CpG site associations to age, BMI, DBP and glucose
Discovery cohorta (n = 11)
Spearman’s rank correlation coefficients
Gene Illumina ID p (Age) p (BMI) p (DBP) p (Glucose)
MCCC1 cg00161968 ns ns ns ns
SKOR2 cg00875989 ns ns ns ns
VGLL3 cg06251539 ns ns ns ns
WSB1 cg08706258 ns ns ns ns
EHMT2 cg09134341 ns ns ns ns
TCF12 cg10146710 ns ns ns 2.81E–02
MAP2K4 cg10596925 ns ns ns ns
FAM54A cg10640093 ns ns ns ns
SORBS1 cg12360759 ns ns ns ns
DDX55 cg15612682 ns ns ns ns
ATXN1L cg16076930 ns ns ns ns
EFEMP1 cg16118212 ns ns ns ns
CRKL cg16500810 ns ns ns 2.08E–02
STEAP3 cg18643762 ns ns ns ns
CPEB4 cg20841073 ns ns ns ns
RHOBTB2 cg21344124 ns ns ns ns
ATXN1 cg21996137 ns ns ns ns
TSSK1B cg22011370 ns ns ns 4.04E–02
SPPL2A cg22295383 ns ns ns ns
BHLHA9 cg23945265 ns ns ns 4.78E–02
CHCHD5 cg25521086 ns ns ns ns
NRTN cg25544164 ns ns ns ns
Abbreviations: DB diastolic blood pressure, ns, not significant, RYGB, Roux-en-Y
gastric bypass, SBP systolic blood pressure
aCohort comprises patients who underwent RYGB surgery. P-values were derived
by analyses of Spearman’s rank correlation coefficients using algorithm AS 89 and
an Edgeworth series approximation. For the variables DBP, BMI and fasting
plasma glucose, percent change in methylation states were correlated with
percent change in these variables, measured before and six months after
RYGB surgery. For the variable age, percent change in methylation states
measured before and six months after RYGB surgery was correlated with age.
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epigenetic profiles [43]. Studies indicate that changes in
leukocyte composition may induce a significant variability
in the DNA methylation pattern observed in the periph-
eral blood [43]. Koestler et al. provided a list of the top 50
differentially methylated CpG sites observed in six im-
portant leukocyte subtypes [44]. None of the newly de-
tected CpG sites belonged to the described group of
CpG sites, which supports the reliability of our results.
Furthermore, we confirmed our findings in more than
539 individuals in a case-control study, making confound-
ing effects on our results due to changes in leukocyte
composition unlikely.
Conclusions
In summary we were able to identify two novel CpG
loci associated with EH that have not yet been de-
scribed in context to HT. Our findings may contribute
to a further understanding of the epigenetic regulatory
mechanisms behind the development of this disease.
Based on our findings we suggest that EHMT2 may
contribute to the vascular pathophysiology of EH by in-
fluencing IL-17 expression in T helper cells. Further
studies are needed to confirm the role of IL-17 in hu-
man EH, and to investigate whether the observed
methylation changes in G9a reflect gene expression
levels, H3K9me2 activity and IL-17 expression levels.
The global role of G9a leaves space for additional regu-
latory functions in HT.
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Fig. 1 The methyltransferase G9a in cooperation with its homologue G9a-like protein (GLP) is responsible for the majority of dimethylation of
H3K9me2. Cells that lack G9a (or GLP) display a drastic reduction in this modification [26]. H3K9me2 acts as a major repressive histone methylation
mark in euchromatin, that affects also the interleukin 17 gene locus, resulting in inhibition of IL-17 expression [27]. Harrison et al. demonstrated
that mice lacking IL-17 do not develop sustained hypertension after treatment with angiotensin II. In contrast to wild-type mice, IL-17−/− mice
do not exhibit an increase in superoxide production and there is no reduction in endothelial-dependent vasodilatation. Furthermore, there was a
reduction in vascular accumulation of leukocytes in IL-17−/− mice, probably due to a reduction of chemotaxis normally induced by IL-17 [35]
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